检查点激酶1抑制剂+低剂量基尿素有效杀死BRAF抑制剂和免疫检查点抑制剂耐药黑色素瘤
Zhen Zeng1, Hung Long Ngo1, Martina Proctor1
1Mater Research Institute, The University of Queensland, Brisbane, Queensland, Australia.
Pigment cell & melanoma research
|August 24, 2023
概括
检查点激酶1 (CHK1) 抑制剂加上低剂量基尿素 (LDHU) 有效向黑色素瘤复制应激. 这种组合有望通过促进抗瘤免疫力来治疗耐药黑色素瘤.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 免疫学 免疫学 免疫学
背景情况:
- 针对性疗法和免疫疗法等黑色素瘤治疗方法面临阻力,限制了患者的选择.
- 复制压力是黑色素瘤的常见特征.
- 现有的治疗方法往往由于获得的抵抗机制而失败.
研究的目的:
- 为了研究结合检查点激酶1 (CHK1) 抑制剂与低剂量基尿素 (LDHU) 在黑色素瘤中的疗效.
- 为了确定这种组合是否可以克服对BRAF抑制剂 (BRAFi) 和免疫检查点抑制剂 (ICI) 的耐药性.
- 评估这种组合在体内对抗瘤免疫反应的影响.
主要方法:
- 使用获得了对BRAFi和ICI耐药性的黑色素瘤细胞系.
- 用CHK1抑制剂加LDHU治疗耐药和敏感的黑色素瘤模型.
- 在体内评估瘤敏感性和免疫反应.
主要成果:
- 抗BRAFi或ICI的黑色素瘤细胞系对CHK1抑制剂+LDHU保持敏感.
- 耐药细胞系的敏感度与父母瘤的敏感度相当.
- 在体内研究表明,BRAFi耐药和BRAFi敏感的瘤对治疗产生了相同的免疫反应.
结论:
- 结合CHK1抑制剂和LDHU是一种潜在的治疗策略,用于抗现行治疗的黑色素瘤.
- 这种组合有效地准黑色素瘤复制压力,并增强抗瘤免疫力.
- CHK1 抑制剂 + LDHU 为耐火性黑色素瘤患者提供了可行的替代方案.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Tumor Immunotherapy
556
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
556


